Excellent healthcare – locally delivered OVERVIEW OF CLINICAL RECOMMENDATIONS FOR ADULTS, PREGNANT WOMEN AND CHILDREN OVERVIEW OF CLINICAL RECOMMENDATIONS.

Slides:



Advertisements
Similar presentations
Group Work Recommendations-When to Start Group C.
Advertisements

The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.
WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
1 Dr Kunal Bagchi Regional Adviser – Nutrition & Food Safety WHO South-East Asia Regional Office Kathmandu, Nepal November 2011.
99.98% of the time patients are on their own “The diabetes self-management regimen is one of the most challenging of any for chronic illness.” 0.02% of.
Country Experience Informing Feasibility Option B+ (Malawi) Tenofovir phase in 1 st line( Zambia) d4T phase out in HIV programmes Raising CD4 threshold.
Use of Antiretroviral Drugs for Treating Pregnant Women and
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
ART stock-outs Francois Venter Wits Reproductive Health & HIV Institute.
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Linda-Gail Bekker The implementation of this project was made possible.
Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations WHO 2013 ARV Guidelines Launch Dr. Meg Doherty, WHO, Geneva.
ART in Resource-limited settings : Progress and Challenges Dr. B. B. Rewari MD,FRCP,FICP,FIACM,FGSI,FIAMS,FIMSA, NPO (ART) India 21 st July 2014, Adult.
The Role of the IATT Optimal Paediatric ARV Formulary and Considerations for New Product Introduction Nandita Sugandhi, M.D. Clinton Health Access Initiative.
Antiretroviral Treatment of Mothers: interrupting vertical transmission Dr Angela Mushavi National PMTCT and Pediatric HIV Care and Treatment Coordinator.
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Treatment of Children and Adolescents Implementation Challenges Annette H. Sohn, MD TREAT Asia/amfAR – Thailand AIDS 2014.
Pediatric HIV Care & Treatment in Uganda A Five-Day Training Course For Health Professionals.
Preliminary findings of a routine PMTCT Option B+ programme in a rural district in Malawi Rebecca M. Coulborn 1, Laura Triviño Duran 1, Carol Metcalf 2,
Global Strategy, Policy and Normative Guidance for POC Diagnostics Gottfried Hirnschall MD, MPH Department of HIV/AIDS, World Health Organization July.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.
THE NEVEREST STUDY AT RAHIMA MOOSA MCH Ashraf Coovadia Adjunct Professor Enhancing Childhood HIV Outcomes (Wits Paediatric HIV Clinics) Rahima Moosa Mother.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Crossroads Hotel 7 th January  All adolescents & adults with HIV infection & CD4 counts less than/equal to 350 cells/mm3, including pregnant women,
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Gottfried Hirnschall Director, HIV Department WHO, Geneva.
ICASA IAS Scaling up Treatment Delivery Programmes: Issues, Challenges & Best Practices Siobhan Crowley HIV Department WHO Geneva.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Integrating ART/PMTCT services into MNCH services to enhance test & treat strategy for HIV infected pregnant and lactating women (Option B+) WHO Satellite.
WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.
Access to Paediatric ARV Formulations Provisions for Children.
Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.
Agenda Introduction- Jessica Rodrigues, IATT Paediatric Treatment Optimization- George Silberry, Senior Technical Advisor for Pediatric HIV, OGAC Optimal.
Developing evidence-based guidelines at WHO. Evidence-based guidelines at WHO | January 17, |2 |
Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.
HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Decentralized, Integrated and Community-Centred Service Delivery.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
Strengthening Integration between RMNCH and HIV services Nuhu Yaqub WHO Tanzania.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)
Scaling up Access to HIV treatment What can we learn for NCDs?
How differentiated care supports “Tx all” and Dr
OVERVIEW OF PREVENTING MOTHER TO CHILD TRANSMISSION OF HIV
WHO perspectives on dolutegravir
Differentiated Service Delivery: Innovating for Impact
2017 Key Considerations for adolescents and children & Key populations
MUHC Innovation Model.
Guideline Development
The role of Dolutegravir in first-line regimens
Closing the Treatment Gap of Children Living with HIV
Rationale: 2nd Line Regimens in Adults
Marco Vitoria HIV Department Geneva
Thokozani Kalua MBBS MSc Malawi Ministry of Health
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Update on global progress in ART
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Excellent healthcare – locally delivered OVERVIEW OF CLINICAL RECOMMENDATIONS FOR ADULTS, PREGNANT WOMEN AND CHILDREN OVERVIEW OF CLINICAL RECOMMENDATIONS FOR ADULTS, PREGNANT WOMEN AND CHILDREN Dr. Philippa Easterbrook 2013 Consolidated ARV Guidelines Dr. Philippa Easterbrook

30 th June 2013

Guideline Dissemination Regional Guidelines Workshops MonthEventDatesLocation JulyStrategic Use of ARVs23-25/07/2013Yogyakarta, Indonesia JulyAFRO East and Southern Africa 23-25/07/2013Pretoria, South Africa AugustPPTCT Asia Regional PMTCT meeting 27-29/08/2013Kathmandu, Nepal AugustPAHO Regional26-28/08/2013Buenos Aires, Argentina SeptemberEMRO Regional11-13/09/2013Casablanca, Morocco SeptemberWPRO/SEARO Consultation16-18/09/2013Beijing, China OctoberEURO29-31/10/2013Istanbul, Turkey NovemberAFRO East and Central Africa 11-13/11/2013Accra, Ghana DecemberICASA7-11/12/2013Cape Town, South Africa

Objectives of presentation WHO guidelines development and key features Recommendations for Adults, pregnant women and children and Overview of Evidence Base and Rationale: When to Start ART What ART to Start (First-Line) What ART to Switch to (Second-Line) How to Monitor ART

30 th June 2013 Find the New 2013 WHO Consolidated ARV Guidelines on

TOPIC WHEN TO START CD4 ≤200 - Consider CD4 ≤ 350 for TB CD4 ≤ 350 -Irrespective CD4 for TB & HBV PMTCTSince weeks AZT; AZT+ 3TC, or single dose NVP 2004 AZT from 28 weeks + single dose NVP AZT from 28 weeks + single dose NVP +AZT/3TC 7days Option A (AZT +infant NVP) Option B (triple ARVs) 1 ST LINE8 options - AZT preferred 4 options - AZT preferred 8 options - AZT or TDF preferred - d4T dose reduction 6 options & FDCs - AZT or TDF preferred - d4T phase out 2 ND LINEBoosted PI ATV/r, DRV/r, FPV/r LPV/r, SQV/r Boosted PI Heat stable FDC: LPV/r, ATV/r VIRAL LOAD TESTING No (Desirable) Yes Tertiary centers Yes Phase in Evolution of WHO ART Guidelines Vitoria M et al, Curr Opin HIV/AIDS 2013 Earlier initiation Simpler treatment Less toxic, more robust regimens Better monitoring Simplified treatment options for pregnant women

Guidance for Programme Managers HOW TO DO IT? Service delivery Diagnostics Drug supply HOW TO DO IT? Service delivery Diagnostics Drug supply HOW TO DECIDE? Prioritization Equity and ethics Monitoring & Evaluation HOW TO DECIDE? Prioritization Equity and ethics Monitoring & Evaluation WHAT TO DO? When to start or switch Which regimen to use How to monitor Co-infections & co-morbidities WHAT TO DO? When to start or switch Which regimen to use How to monitor Co-infections & co-morbidities Operational WHO 2013 Consolidated ARV Guidelines

Concept Behind Consolidation… Consolidation of new with existing guidance Consolidation across populations and ages Consolidation along the continuum of care

Scoping the document Disclosure and management of secondary interests Formulation of the recommendations (GRADE) Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use Dissemination, implementation (adaptation) Dissemination, implementation (adaptation) Evaluation of impact Plan for updating Formulation of the questions (PICO) and choice of the relevant outcomes Formulation of the questions (PICO) and choice of the relevant outcomes Evidence retrieval, assessment and synthesis (systematic review(s)) Evidence retrieval, assessment and synthesis (systematic review(s)) GRADE - evidence profile(s) WHO Guideline Development PICO: requires specifics of Population, Intervention, Comparator & Outcomes 6 Setting up Guideline Development Group and External Review Group 2

Scoping the document Disclosure and management of secondary interests Formulation of the recommendations (GRADE) Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use Dissemination, implementation (adaptation) Dissemination, implementation (adaptation) Evaluation of impact Plan for updating Setting up Guideline Development Group and External Review Group 2 3 Guideline Development at WHO PICO: requires specifics of Population, Intervention, Comparator & Outcomes 6 Formulation of the questions (PICO) and choice of the relevant outcomes Formulation of the questions (PICO) and choice of the relevant outcomes 4 Evidence retrieval, assessment and synthesis (systematic review(s)) Evidence retrieval, assessment and synthesis (systematic review(s)) GRADE - evidence profile(s) 5

G rades of R ecommendation A ssessment, D evelopment and E valuation

Scoping the document Disclosure and management of secondary interests Dissemination, implementation (adaptation) Dissemination, implementation (adaptation) Evaluation of impact Plan for updating Setting up Guideline Development Group and External Review Group Formulation of the questions (PICO) and choice of the relevant outcomes Formulation of the questions (PICO) and choice of the relevant outcomes Evidence retrieval, assessment and synthesis (systematic review(s)) Evidence retrieval, assessment and synthesis (systematic review(s)) GRADE - evidence profile(s) Guideline development at WHO PICO: requires specifics of Population, Intervention, Comparator & Outcomes Formulation of the recommendations (GRADE) Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use Including explicit consideration of:  Benefits and harms  Values and preferences  Resource use 6

Modelling of impact and cost-effectiveness Earlier ART and different testing strategies Different populations  General population  Serodiscordant couples  Pregnant women  IDUs, sex workers and MSMs  HIV-HBV and HCV Different settings  Generalised (South Africa, Zambia)  Concentrated (Vietnam, India)

Values and Preferences 87 participants Malawi and Uganda Adult (n=98) & Paediatric (n=342): 9 Global implementers (ANEPA, ANECA, CHAI, CDC, EGPAF, ICAP, IeDEA, MSF, PATH) Health care worker consultation Community consultation Option B+ Focus Groups E-survey (n=1088), E-forums (n=955) 6 UN languages E-survey: 21% LIC, 58% MIC; 45% PLHIV; Topics  Earlier ARV initiation  Lifelong ART in pregnant women  Task-shifting and integrated services  Role of communities